The prospect for a soft landing and falling rates remain strong, but timing is still uncertain, notes Marc Pinto. He talks about how the focus on quality companies has proven to be a great strategy in uncertain periods. He also goes over opportunities in tech outside of the mega caps. He’s very positive on healthcare, biotech in particular.